NFKB1 and tuberculosis: Inhibition of MAPK either with SB20358, a p38-MAPK inhibitor, or PD98059, an ERK inhibitor, significantly suppressed NF-κB activation with a concomitant increase in the HSP70 expression in AM of TB patients (Fig. 3C).